BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
BioXcel Therapeutics's total debt was $104.45M at Jun 30, 2026. For fiscal 2025 it was $109.59M, up 6.9% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.59M | +6.9% |
| FY2024 | Dec 31, 2024 | $102.51M | +1.9% |
| FY2023 | Dec 31, 2023 | $100.60M | +8.1% |
| FY2022 | Dec 31, 2022 | $93.05M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $104.45M | -3.9% |
| Q1 FY2026 | Mar 31, 2026 | $100.29M | -5.0% |
| Q4 FY2025 | Dec 31, 2025 | $109.59M | +6.9% |
| Q3 FY2025 | Sep 30, 2025 | $109.13M | +4.5% |
| Q2 FY2025 | Jun 30, 2025 | $108.69M | +5.5% |
| Q1 FY2025 | Mar 31, 2025 | $105.53M | +3.8% |
| Q4 FY2024 | Dec 31, 2024 | $102.51M | +1.9% |
| Q3 FY2024 | Sep 30, 2024 | $104.44M | +5.4% |
| Q2 FY2024 | Jun 30, 2024 | $103.01M | +6.4% |
| Q1 FY2024 | Mar 31, 2024 | $101.63M | +6.9% |
| Q4 FY2023 | Dec 31, 2023 | $100.60M | +8.1% |
| Q3 FY2023 | Sep 30, 2023 | $99.09M | +8.1% |
| Q2 FY2023 | Jun 30, 2023 | $96.85M | +58.6% |
| Q1 FY2023 | Mar 31, 2023 | $95.06M | – |
| Q4 FY2022 | Dec 31, 2022 | $93.05M | – |
| Q3 FY2022 | Sep 30, 2022 | $91.70M | – |
| Q2 FY2022 | Jun 30, 2022 | $61.08M | – |
See a number that looks wrong?